PM Tracker

There's more to the Alzheimer's disease pipeline than the three leading therapies: Eisai and Biogen’s lecanemab, Genentech’s gantenerumab and Eli Lilly’s donanemab. The Alzheimer’s Association scraped data from the ClinicalTrials.gov database and found that there are 143 drugs in the pipeline—not just three—spread across 172 clinical trials.

Messages on the popular social media site accused the retail pharmacy of “putting politics over patients" by refusing to fill a prescription for non-abortion related care. Other drugstores restricting reproductive health care raise questions about retail’s role in the abortion debate.

Novo Nordisk is handing over $1.1 billion in cash to buy Forma Therapeutics in hopes that the clinical-stage biotech’s assets will help build a leading portfolio in sickle cell disease.

The startups selected pitched solutions aimed at improving access to care and addressing social determinants of health. The program will run four weeks and culminate with a demo day at HLTH 2022.

Medtronic's Adapt trial put the algorithm-equipped MiniMed 780G insulin pump to the test against one standard of care for Type 1 diabetes management—a combination of multiple daily insulin injections and intermittent check-ins with a continuous glucose monitor.

Andreas "Drew" Panayiotou joins Pfizer in the pharma’s inaugural biopharma global chief marketing officer role. In this capacity, Panayiotou will initiate building commercial infrastructure, and add new innovative engagement channels, tools, and digital solutions.

Fresh off reporting the promising results of a phase 3 study of its constipation relief device, Vibrant Gastro is keeping things moving.

CMS proposed a new rule outlining requirements for states to ensure that Medicaid and CHIP beneficiaries are able to hold on to their coverage.

Novartis' head of R&D Jay Bradner is stepping down after seven years at the helm, with plans to pursue new ventures. For his replacement, the company tapped Merck executive Fiona Marshall, who will take over in November.

United Therapeutics has struck a blow to Liquidia Technologies’ generic formulation of Tyvaso. With a court ruling the generic infringes a United patent, Liquidia faces the prospect of being kept off the market until 2027—unless it gets the decision overturned or prevails in a related dispute.

In a fitting move for the maker of heart-valve-opening technology, California-based startup JenaValve is currently on a mission to open up the device’s pathway to the commercial market.

How a new app brings the power of CRM to a leading lab instruments provider’s field service engineers

Today’s healthcare systems are adapting to an ever changing landscape with declining margins, M&A pressures, and the need for staff flexibility due to shortages. Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens.

This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series).

How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation

Improve your congress competitive intelligence and cut down costs by 50%

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals.

Set a solid foundation for successful scale-up of buffer preparation.

The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services.

See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.